Medline Future Growth
Future criteria checks 3/6
Medline is forecast to grow earnings and revenue by 23.5% and 7.3% per annum respectively. EPS is expected to grow by 18.9% per annum. Return on equity is forecast to be 9.6% in 3 years.
Key information
23.5%
Earnings growth rate
18.87%
EPS growth rate
| Medical Equipment earnings growth | 17.3% |
| Revenue growth rate | 7.3% |
| Future return on equity | 9.58% |
| Analyst coverage | Good |
| Last updated | 20 Aug 2026 |
Recent future growth updates
Recent updates
MDLN: FDA Compliance And Legal Overhang Will Shape Future Upside Potential
Analysts have trimmed their price target on Medline to $44.62 from $50.65 as they now factor in a slightly higher discount rate, more moderate revenue growth, a lower profit margin outlook, and a marginally higher future P/E assumption. What’s in the News for Medline Medline Inc.
Expanded Supply Chain Network And Quality Remediation Will Support Stronger Long-Term Prospects
Catalysts About Medline Medline is a vertically integrated manufacturer and distributor of medical surgical products that supplies health care providers across acute, non-acute and retail channels. What are the underlying business or industry changes driving this perspective?MDLN: FDA Warning Letter Risk Will Shape Future Opportunity
Analysts have adjusted their price target for Medline slightly lower, to about $50.65 from roughly $51.70, reflecting updated views on discount rates, profit margins, fair value, and future P/E assumptions. What’s in the News for Medline Kaplan Fox & Kilsheimer LLP announced a securities investigation into Medline Inc.Prime Vendor Contracts And Automation Investments Will Reshape Long Term Earnings Profile
Catalysts About Medline Medline is a vertically integrated manufacturer and distributor of medical supplies and supply chain services for health care providers across acute, non-acute and international markets. What are the underlying business or industry changes driving this perspective?Medline: A Lack Of Compelling Risk-Reward Makes Me Cautious
Summary Medline delivered strong Q4 momentum and 2025 sales growth, but recent margin pressure has left profits largely flat. Medline guides for 8-9% organic sales growth and modest adjusted EBITDA gains in 2026, yet margin compression remains a material concern. Selling shareholders, including Blackstone and Carlyle, recently offloaded a significant stake post lock-up, highlighting valuation sensitivity. At $44 per share, Medline trades at 31-33x forward earnings, a demanding multiple given segment margin discrepancies and leverage. Read the full article on Seeking AlphaEarnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 36,283 | 1,725 | 2,311 | 2,858 | 19 |
| 12/31/2027 | 33,672 | 1,599 | 2,005 | 2,629 | 25 |
| 12/31/2026 | 31,232 | 977 | 1,387 | 1,914 | 25 |
| 6/27/2026 | 29,939 | 701 | 1,546 | 1,992 | N/A |
| 3/28/2026 | 29,140 | 975 | 996 | 1,474 | N/A |
| 12/31/2025 | 28,432 | 1,159 | 1,264 | 1,744 | N/A |
| 9/27/2025 | 27,429 | 1,266 | 1,009 | 1,442 | N/A |
| 6/28/2025 | 26,702 | 1,268 | 1,089 | 1,528 | N/A |
| 3/29/2025 | 25,984 | 1,229 | 1,512 | 1,891 | N/A |
| 12/31/2024 | 25,507 | 1,200 | 1,405 | 1,769 | N/A |
| 12/31/2023 | 23,231 | 234 | 1,400 | 1,685 | N/A |
| 12/31/2022 | 21,448 | -25 | -67 | 187 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MDLN's forecast earnings growth (23.5% per year) is above the savings rate (3.7%).
Earnings vs Market: MDLN's earnings (23.5% per year) are forecast to grow faster than the US market (16.9% per year).
High Growth Earnings: MDLN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MDLN's revenue (7.3% per year) is forecast to grow slower than the US market (12.9% per year).
High Growth Revenue: MDLN's revenue (7.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MDLN's Return on Equity is forecast to be low in 3 years time (9.6%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/21 01:02 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/27 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medline Inc. is covered by 31 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eric Coldwell | Baird |
| Glen Santangelo | Barclays |
| Lee Hambright | Bernstein |